Narrow Your Results

Strategy

Sections

Showing 1 - 3 of 3 Results for "CD4 count"

Results

Adherence and Support Gap
Major evidence gaps exist on adherence-enhancing interventions for long-term effectiveness and at higher CD4 counts. A rapid systematic review by WHO found that while ART requires life-long therapy, the majority of studies have lasted two years or less.
Adherence and Support
1 study
Specific additional adherence support is needed for those who initiate ARVs at CD4 counts above 250. A review of forty randomized trials found that no consensus exists on how to effectively increase adherence, particularly among those living with HIV with no symptoms. A study found that initiating ARVs at CD4 above 250 was associated with increased odds and number of treatment interruptions and increased odds of persistent increased viral load within the first three months of ARV initiation.
Adherence and Support
1 study
Interventions are needed to enhance counseling to successfully prepare patients for lifelong therapy. Studies have found that patients were not well prepared for life-long therapy; that adherence rates decreased over time and hospital costs increased for those who were less adherent. A study found that patients believed that ART killed other patients, not understanding that initiating ART at high viral loads and low CD4 counts reduces the likelihood of survival.
Adherence and Support
1 study